Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Lung cancer, particularly non-small lung cancer (NSCLC), is one of the most common malignant tumors worldwide and is associated with high mortality in advanced stages. Lung adenocarcinoma is the most frequent NSCLC subtype. Among these common metastatic sites, brain metastases and leptomeningeal metastases have a particularly debilitating impact on patients' survival and quality of life. We describe the clinical course of a 43-year-old man with stage IV lung adenocarcinoma who developed crizotinib-induced pancreatitis and leptomeningeal metastases, both are rare. Imaging of the brain was done due to the development of neurological symptoms and demonstrated metastatic leptomeningeal enhancement. The patient's condition continued to worsen and resulted in sudden cardiac arrest. This case demonstrates a rare complication of NSCLC-leptomeningeal metastasis-and the importance of a multidisciplinary team approach in managing advanced NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409375 | PMC |
| http://dx.doi.org/10.1016/j.radcr.2025.08.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of miRNAs on epithelial-mesenchymal transition in lung cancer and the latest advances in their use as diagnostic markers.
J Cancer Res Clin Oncol
September 2025
Inner Mongolia Medical University Affiliated Hospital, Hohhot, 010030, Inner Mongolia, China.
Purpose: Lung cancer is currently the most common malignant tumor worldwide and one of the leading causes of cancer-related deaths, posing a serious threat to human health. MicroRNAs (miRNAs) are a class of endogenous non-coding small RNA molecules that regulate gene expression and are involved in various biological processes associated with lung cancer. Understanding the mechanisms of lung carcinogenesis and detecting disease biomarkers may enable early diagnosis of lung cancer.
View Article and Find Full Text PDFAllele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance.
J Immunother Cancer
September 2025
Affini-T Therapeutics Inc, Watertown, Massachusetts, USA.
T-cell receptors (TCRs) recognize antigens derived from fragments of somatically expressed proteins that are degraded by the proteasome and presented by specific human leukocyte antigen (HLA) molecules. Recent therapeutic advances using the TCR as a tumor-targeting moiety have focused attention on loss of heterozygosity (LOH) as a potential resistance mechanism. Allele-specific LOH, rather than allele-agnostic, is particularly pertinent, but rarely evaluated.
View Article and Find Full Text PDFConcomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.
JAMA Netw Open
September 2025
Oncostat U1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France.
Importance: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.
Objective: To explore the association of comedications with overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).
Design, Setting, And Participants: This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database.
Prevalence of Molecular Mutations in Non-Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion.
J Immunother Precis Oncol
August 2025
Tawam Hospital, AlAin, UAE.
Over the past decade, the discovery of immunotherapy and targeted therapy has set new standards for the management of advanced non-small cell lung cancer (NSCLC). This study aims to investigate the prevalence of , , , , , , and mutations in patients with NSCLC within the Middle East and North Africa (MENA) region and to assess the current state of molecular testing and targeted treatments in the Gulf Cooperation Council (GCC) region. The systematic literature review was performed using PubMed, Google Scholar, and Google searches to identify studies on the prevalence of , , , , , , and mutations in patients with NSCLC in the MENA region.
View Article and Find Full Text PDFOlder Adult Participation in Early-Phase Lung Cancer Clinical Trials, 1998 to 2020.
JTO Clin Res Rep
October 2025
Division of Hematology/Oncology, Department of Medicine, University of California Davis, Sacramento, California.
Objectives: Despite advances, lung cancer treatment remains associated with substantial toxicity. Early-phase clinical trials inform the safety and efficacy of novel lung cancer treatments. Although older adults represent most patients with lung cancer, and they are underrepresented in phase 3 trials, age disparity in early-phase lung cancer trials is ill-defined.
View Article and Find Full Text PDF